generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia
Trial Timeline
Mar 1, 2010 → Apr 1, 2011
NCT ID
NCT01624207About generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®) is a approved stage product being developed by Yuhan for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01624207. Target conditions include Hypercholesterolemia.
What happened to similar drugs?
20 of 20 similar drugs in Hypercholesterolemia were approved
Approved (20) Terminated (2) Active (0)
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01624207 | Approved | Completed |
Competing Products
20 competing products in Hypercholesterolemia